July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Caspase-2 increases in RGC and its inhibition protects against optic nerve degeneration in a murine repeated blast ocular trauma model.
Author Affiliations & Notes
  • Chloe Naomi Thomas
    Neuroscience and Ophthalmology, University of Birmingham, Birmingham, ENGLAND, United Kingdom
  • Tonia S Rex
    Vanderbilt University Medical Center, Vanderbilt Eye Institute, Nashville, Tennessee, United States
  • Alexandra Bernardo-Colon
    Vanderbilt University Medical Center, Vanderbilt Eye Institute, Nashville, Tennessee, United States
  • Richard J Blanch
    Neuroscience and Ophthalmology, University of Birmingham, Birmingham, ENGLAND, United Kingdom
  • Zubair Ahmed
    Neuroscience and Ophthalmology, University of Birmingham, Birmingham, ENGLAND, United Kingdom
  • Footnotes
    Commercial Relationships   Chloe Thomas, None; Tonia Rex, None; Alexandra Bernardo-Colon, None; Richard Blanch, None; Zubair Ahmed, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4450. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chloe Naomi Thomas, Tonia S Rex, Alexandra Bernardo-Colon, Richard J Blanch, Zubair Ahmed; Caspase-2 increases in RGC and its inhibition protects against optic nerve degeneration in a murine repeated blast ocular trauma model.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4450.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Caspase-2 is activated in retinal ganglion cells (RGC) in optic nerve crush (ONC) model and after blunt ocular trauma. Caspase-2 also promotes neuronal degeneration in Alzheimer’s disease. RGC are CNS neurons and do not regenerate after injury, thus after injury RGC and their axons (which form the optic nerve) are not replaced, which can lead to potentially irreversible blindness. Our aim was to determine if caspase-2 is activated in a murine repeated blast ocular trauma model and whether its inhibition using a siRNA to caspase-2 (siCASP2) prevents RGC and optic nerve degeneration.

Methods : We exposed the left eye of anesthetised C57Bl/6 mice to repeated blast of overpressure air (2 x 15psi blasts in quick succession, 24 hours apart over 3 days). Sham mice were exposed to anaesthetics but not the blast wave. Eyes were collected 1 month after blasts and immunostained for caspase-2 (n=4). The siCASP2 was intravitreally injected 2 days before injury and every 7 days during the experiment until collection. Eyes were sectioned and the RGC were immunolabelled, and optic nerves were resin embedded, sectioned, and stained with p-phenylenediamine (PPD) and toluidine blue (n=5 optic nerves per group). Total RGC and healthy and degenerating axons were counted. Optical coherence tomography (OCT) imaging of the retina was performed throughout the experiment. siCASP2 was generously donated by Quark Pharmaceuticals Inc, without interference with study design or its outcome.

Results : Caspase-2 immunofluorescence increased in RGC in 1 month C57Bl/6 mouse exposed to repeated blast, compared to sham. There was a decrease in total degenerating axons in siCASP2 treated optic nerves compared to siGFP control (80 ± 18 compared to 166 ± 22; n=5; students t-test p<0.05). There was no difference in total axons (p>0.05). This suggests that siCASP2 prevents axonal degeneration after repeated blast injury. OCT imaging showed that intravitreal injections and repeated blast does not affect gross retinal structure.

Conclusions : Caspase-2 is increased in RGC after repeated blast ocular trauma and siCASP2 treatment protects against degeneration of axons in the optic nerve. These data suggest that this may be a common pathogenic pathway in both blunt and blast force induced neurotrauma.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×